Building National Brand and Product Portfolio slide image

Building National Brand and Product Portfolio

ONE OF THE MOST STRATEGICALLY POSITIONED MSOS Addressable market is >52% of the US population() with significant upside potential Columbia Care US Footprint Columbia Care Addressable Market (2) Adult Use Anticipated Medical Only Adult Use & Medical Pursuit Activity State Population (M) Est 2023 Sales (US$M) Est 2027 Sales (US$M) Status Licenses California 41.3 4,978.5 $ 6,576.5 Florida 22.2 $ 2,563.5 $ 4,503.3 Both Medical Unlimited Limited Illinois 12.7 $ 2,167.3 $ 2,632.7 Both Limited Massachusetts 7.0 1,799.3 $ 1,878.8 Both Limited Colorado 6.3 1,657.1 $ 1,833.8 Both Unlimited $35B+ Arizona 7.3 1,290.6 1,420.3 Both Limited New York 20.1 1,258.7 5,000.0(2) Both* Limited Projected 2027 TAM in Licensed US States(2) Pennsylvania 12.9 $ 1,204.9 $ 1,931.4 Medical Limited New Jersey 9.1 $ 1,121.6 $ 3,000.0(2) Both Limited Ohio 11.7 $ 518.3 $ 1,604.0 Medical Limited Maryland 6.2 479.9 $ 1,311.2 Both* Limited Conversion to Medical and Adult-Use Offers Significant Upside Columbia Care has experienced 3x-4x top-line revenue growth in states that have already converted from medical-only to medical and adult-use Adult-use sales launched in New Jersey (April 2022), in New York (January 2023, but MSO participation is pending), and in Maryland (July 2023) Columbia Care's strategic footprint is well positioned for the anticipated conversion of additional markets Utah Virginia West Virginia *Legislation passed, Columbia Care first sales in Adult Use pending 3.3 161.2 298.0 Medical Limited 8.7 $ 121.6 3,000.0(2) Both* Limited 1.8 52.2 83.7 Medical Limited Washington DC 0.7 $ 50.8 $ 133.8 Medical Limited Delaware 1.0 $ 39.8 $ 149.2 Medical Limited TOTAL 172.3 $ 19,465.3 $ 35,356.7 1) 2) US Census Bureau, Company estimates, Gallup poll, as of Nov 2020 Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, company estimates 8 Columbia Care
View entire presentation